-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
EMR delivered operating EPS growth of 4% Y/Y to $1.54, though underlying sales growth moderated to 0.5%, impacted by the U.S.-Iran conflict according to management. The beat was supported by share buyback activity. We see 5% underlying orders growth signaling a future recovery, with bookings centered in the high-margin Software & Systems business. Management expects Software segment profitability to enter modest recovery in 2H FY 26. The Software & Systems platform delivered 4% reported growth, with Test & Measurement achieving 16% reported growth, reflecting sustained demand in EMR's growth verticals including semiconductor and aerospace markets. Geographic performance revealed mixed fortunes, with Americas leading growth at 5% Y/Y, while Europe declined 4% and Asia/MEA fell 5%, reflecting broader geopolitical tensions. Adjusted segment EBITA margin compressed 40 bps Y/Y to 27.6% despite favorable mix shift toward higher-margin Software & Systems, with Software margins declining 250 bps to 29.2%.